Last reviewed · How we verify

NCT05880355

Multimodality Cardiovascular Imaging for the Translation of Therapies for Vascular Activation After MI

Not yet recruiting EARLY_PHASE1 Last updated 4 June 2025
What this trial tests

EARLY_PHASE1 trial testing Dapansutrile in Myocardial Infarction in 60 participants. Not yet recruiting.

Timeline
1 April 2026
Primary endpoint
31 December 2028
30 January 2029

Quick facts

Lead sponsorUniversity of Virginia
PhaseEARLY_PHASE1
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment60
Start date1 April 2026
Primary completion31 December 2028
Estimated completion30 January 2029
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Virginia

Who can join

Adults 25 to 99, any sex, with Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Subjects with urgently reperfused type I myocardial infarction (MI) will be recruited and randomized to receive either placebo or the oral inflammasome (NLRP3) inhibitor dapansutrile. The primarily outcome measure will be carotid plaque volume change over 6 months; secondary outcome measures will be plaque inflammatory activity and coronary microvascular function.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

  1. NLRP3 inflammasome: a key player in the pathogenesis of life-style disorders.
    Ramachandran R, Manan A, Kim J, Choi S. · · 2024 · cited 67× · PMID 38945951 · DOI 10.1038/s12276-024-01261-8
  2. Inflammasomes in neurodegenerative diseases.
    Wang Q, Yang S, Zhang X, Zhang S, et al · · 2024 · cited 13× · PMID 39710713 · DOI 10.1186/s40035-024-00459-0
  3. Aldosterone: From Essential Tubular Regulator to Pathological Driver-Physiology, Disease, and Therapeutic Advances.
    Strizzi CT, D'Ambrosio V, Grandaliano G, Pesce F. · · 2025 · cited 2× · PMID 41009398 · DOI 10.3390/ijms26188829
  4. Nucleotide-binding domain, leucine-rich repeat, and pyrin domain-containing protein 3 inflammasome: From action mechanism to therapeutic target in clinical trials.
    Zhang CY, Liu S, Sui YX, Yang M. · · 2025 · cited 1× · PMID 39958558 · DOI 10.4251/wjgo.v17.i2.100094
  5. The NLRP3 Inflammasome: Mechanisms of Activation, Regulation, and Therapeutic Opportunities.
    Zou C, Jiang S, Li H, Zhao K, et al · · 2026 · PMID 41799937 · DOI 10.1002/mco2.70660

Verify or expand the search:

Other trials of Dapansutrile

Trials testing the same drug.

Other recruiting trials for Myocardial Infarction

Currently open trials in the same condition.

Other University of Virginia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05880355.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing